NCT05601700招募中3 期
Letrozole for Estrogen/Progesterone Receptor Positive Low-grade Serous Epithelial Ovarian Cancer: a Randomized Phase III Trial (LEPRE Trial)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 132
- 试验地点
- 18
- 主要终点
- Progression-free survival (PFS)
研究概览
简要总结
This is an Italian, multicenter, randomized, open-label phase III trial which will evaluate if Letrozole is superior to standard adjuvant chemotherapy in patients with hormone receptor positive low-grade serous epithelial carcinoma of the ovary (LGSCO).
The hypothesis is that letrozole will significantly prolong median progression free survival (PFS) compared with the standard chemotherapy treatment, namely carboplatin AUC 5 and paclitaxel 175 mg/m2.
详细描述
Primary objective:
To determine if letrozole is superior to standard chemotherapy in terms of progression-free survival (PFS) in the first line treatment of patients with advanced low-grade serous epithelial ovarian carcinoma positive for estrogen and/or progesterone receptors.
Secondary objectives:
- to evaluate the response of tumor to letrozole compared with standard chemotherapy in terms of objective response rate (ORR);
- to test the predictive effect of ER and PgR on response to letrozole in terms of PFS and ORR;
- to evaluate the possible negative association between the effect of letrozole, in terms of PFS and ORR, and the proliferative index Ki67;
- to evaluate the impact of letrozole compared with the impact of standard chemotherapy on patients' health related quality of life evaluated by Menopausal Quality of Life Questionnaire (MENQOL);
- to evaluate the impact of letrozole compared with standard chemotherapy on patients' musculoskeletal pain evaluated by Brief Pain Inventory - Short Form (BPISF);
- to evaluate the effect on overall survival (OS). As most patients will recur and will be switched to chemotherapy and vice versa, OS is not expected to be significantly different;
- to evaluate the safety of letrozole compared with standard chemotherapy according to CTCAE v 5.0.
Translational objectives:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years. I -
- •Newly diagnosed, low-grade serous carcinoma of the ovary including cancer of fallopian tube and peritoneum (invasive micropapillary serous carcinoma or invasive grade 1 serous carcinoma). This is to be confirmed via nuclear p53 immunohistochemistry testing by a central pathology review performed at the Coordinating Centre.
- •Immunohistochemically determined positivity (≥ 10%) for ER and/or PgR expression. This is to be confirmed by centralized review.
- •Patients must have undergone an upfront surgery with maximal cytoreductive effort, with either optimal or suboptimal residual disease status.
- •Stage III-IV according to 2018 FIGO classification. For proper staging:
- •Patients must have undergone contrast-enhanced CT-scan of the chest, abdomen and pelvis within 28 days prior to randomization. If CT-scan is not recommended (e.g. for allergy to contrast agent) MRI or 18F-FDG PET/CT-scan are allowed.
- •The imaging evaluation must be accompanied by an anamnestic and physical examination within 14 days prior to randomization.
- •Postmenopausal, defined as any of the following criteria:
- •Patients who underwent bilateral salpingo-oophorectomy;
- •Monolateral salpingo-oophorectomy, amenorrhea for 12 or more consecutive months and age ≥60 years;
- •Monolateral salpingo-oophorectomy, amenorrhea for 12 or more consecutive months, age <60 years and FSH and serum estradiol levels within the laboratory's reference ranges for post-menopausal women.
- •Randomization must take place within 60 days of primary cytoreductive surgery.
- •Eastern Cooperative Oncology Group - performance status (ECOG-PS) 0-
- •To be able to take oral medications.
- •Adequate bone marrow, hepatic and renal functions as defined below:
- •Absolute neutrophil count (ANC) ≥ 1500/mm3
- •Platelets ≥ 100,000/mm3
- •Hemoglobin ≥ 10.0 g/dL
- •Total bilirubin ≤ 1.5 x Upper Limit of Normal (ULN)
- •ALT and AST ≤ 3.0 x ULN
- •Alkaline phosphatase ≤ 2.5 x ULN
- •Albumin ≥ 2.8 g/dL
- •Serum creatinine ≤ 1.5 x ULN.
- •Written informed consent obtained prior to any study-specific procedure.
排除标准
- •Other malignancy within the last 5 years, except for non-melanoma skin cancer adequately treated.
- •Neoadjuvant chemotherapy or radiotherapy for the treatment of this disease.
- •Previous hormonal therapy for the treatment of this disease.
- •Known hypersensitivity to letrozole or known hypersensitivity/intolerance to carboplatin/paclitaxel therapy.
- •Active or uncontrolled systemic infection.
- •Known central nervous system metastases.
- •Severe cardiac disease, such as myocardial infarction or unstable angina within 6 months prior to randomization.
- •New York Heart Association (NYHA) Class III or greater congestive heart failure.
- •Neuropathy grade 2 or higher.
- •History of fractures of the spine or femur not properly treated.
- •Known osteoporosis (dual-energy x-ray absorptiometry (DEXA) of the femoral neck T score of -2.5 or lower) not adequately treated with bisphosphonates or RANKL inhibitors.
- •Concomitant use of inducers of CYP3A4 (e.g. phenytoin, rifampicin, carbamazepine, phenobarbital, and St. John's Wort) which may reduce exposure to letrozole. Concomitant use of medicinal products with a narrow therapeutic index that are substrates for CYP2C19 (e.g. phenytoin, clopidrogel) that may have their systemic serum concentrations altered by letrozole.
- •Concurrent severe medical problems or any condition that would significantly limit full compliance with the study.
研究组 & 干预措施
Experimental arm
Experimental
Letrozole 2.5 mg daily, per os, until progression or up to 60 months, whichever comes first
干预措施: Letrozole tablets (Drug)
Control arm
Active Comparator
Carboplatin AUC 5 + Paclitaxel 175 mg/mq, IV, on day 1 every 21 days, for 6-8 cycles.
干预措施: carboplatin AUC 5 and paclitaxel 175 mg/m2 (Drug)
结局指标
主要结局
Progression-free survival (PFS)
时间窗: 54 months up to 84 months
the time from the date of randomization to the date of local or regional relapse, distant metastasis, or death from any cause, whichever comes first. Patients not recurred, not progressed or not died while on study or patients lost to f-up will be censored at their last disease assessment date.
次要结局
- Objective Response Rate (ORR)(54 months up to 84 months)
- Predictive effect of ER and PgR (% expression) on response to letrozole in terms of PFS and ORR(54 months up to 84 months)
- Clinical Benefit (CB)(54 months up to 84 months)
- Overall survival (OS)(54 months up to 84 months)
- Safety (Adverse Events)(54 months up to 84 months)
研究者
Andrea DeCensi
Medical Oncology Director
Ente Ospedaliero Ospedali Galliera
研究点 (18)
Loading locations...
相似试验
已完成
3 期
Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast CancerBreast CancerNCT00332852Novartis Pharmaceuticals655
已完成
3 期
Safety/Efficacy of Letrozole Monotherapy or in Combination With Zoledronic Acid as Extended Adjuvant Treatment of Postmenopausal Patients With Primary Breast CancerPostmenopausalOsteoporosisNCT00332709Novartis83
终止
3 期
Trial of Endocrine Against Locoregional Therapy First in Postmenopausal Women With Early Breast CancerOperable Breast NeoplasmsNCT00908531Danish Breast Cancer Cooperative Group123
已完成
4 期
Letrozole Versus Clomifene Citrate for Ovulation InductionPolycystic Ovarian SyndromeInfertilityNCT00478504University of Nottingham159
已完成
4 期
Letrozole in Treating Postmenopausal Women With Metastatic Breast CancerBreast CancerNCT00014638Novartis